Roy N Alcalay Selected Research

Glucosylceramidase (Glucocerebrosidase)

11/2022	Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy.
1/2022	Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers.
1/2022	WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson's Disease Monocytes.
1/2022	Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson's Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial.
1/2022	Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.
1/2021	LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease.
1/2021	Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression.
1/2021	Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease.
10/2020	Longitudinal Measurements of Glucocerebrosidase activity in Parkinson's patients.
1/2020	Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Roy N Alcalay Research Topics

Disease

65	Parkinson Disease (Parkinson's Disease) 11/2022 - 12/2009
9	Gaucher Disease (Gaucher's Disease) 01/2022 - 02/2014
6	Cognitive Dysfunction 01/2020 - 08/2010
5	Parkinsonian Disorders (Parkinsonism) 01/2021 - 11/2012
3	Multiple System Atrophy 09/2021 - 07/2017
3	Dystonia (Limb Dystonia) 01/2021 - 03/2013
3	Disease Progression 11/2020 - 01/2017
2	Inflammation (Inflammations) 03/2022 - 01/2022
2	Lewy Body Disease (Lewy Body Dementia) 01/2020 - 11/2017
2	Movement Disorders (Movement Disorder) 01/2020 - 01/2014
2	Alzheimer Disease (Alzheimer's Disease) 01/2019 - 05/2012
2	Dementia (Dementias) 07/2017 - 08/2010
2	Essential Tremor (Essential Tremors) 07/2016 - 02/2010
2	Tremor (Tremors) 09/2014 - 04/2014
1	Confusion (Bewilderment) 01/2022
1	Panic Disorder (Panic Attack) 01/2022
1	Type C Niemann-Pick Disease (Niemann Pick Disease, Type C) 01/2020
1	Rare Diseases (Rare Disease) 01/2020
1	Traumatic Brain Injuries (Traumatic Brain Injury) 01/2019
1	Neoplasms (Cancer) 01/2019
1	Nervous System Diseases (Neurological Disorders) 01/2019
1	Dopa-responsive Dystonia 01/2019
1	Fabry Disease (Fabry's Disease) 03/2018
1	REM Sleep Behavior Disorder 01/2018
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2018
1	Glycogen Storage Disease Type II (Pompe's Disease) 01/2018
1	Synucleinopathies 07/2017
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2017
1	Sleepiness 10/2016
1	Restless Legs Syndrome (Restless Legs) 06/2015
1	Osteonecrosis (Kienbock's Disease) 09/2014
1	Necrosis 03/2013
1	Asthma (Bronchial Asthma) 07/2011
1	Brachial Plexus Neuritis (Parsonage Turner Syndrome) 05/2010

Drug/Important Bio-Agent (IBA)

26	Glucosylceramidase (Glucocerebrosidase)IBA 11/2022 - 02/2010
21	Biomarkers (Surrogate Marker)IBA 04/2022 - 10/2015
13	Leucine (L-Leucine)FDA Link 01/2022 - 02/2010
12	Phosphotransferases (Kinase)IBA 01/2022 - 02/2010
9	EnzymesIBA 11/2022 - 03/2013
7	SynucleinsIBA 09/2021 - 09/2014
4	Proteins (Proteins, Gene)FDA Link 03/2022 - 01/2017
4	Levodopa (L Dopa)FDA LinkGeneric 11/2020 - 12/2009
3	CholesterolIBA 03/2022 - 12/2015
2	LipidsIBA 04/2022 - 11/2017
2	Biological ProductsIBA 04/2022 - 03/2013
2	sphingosyl beta-glucosideIBA 01/2022 - 01/2022
2	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 01/2019
2	CytokinesIBA 01/2021 - 11/2016
2	SaposinsIBA 01/2020 - 12/2018
2	AcidsIBA 01/2019 - 01/2018
2	alpha-SynucleinIBA 07/2017 - 06/2012
2	Peptides (Polypeptides)IBA 01/2017 - 01/2017
2	Amyloid (Amyloid Fibrils)IBA 01/2016 - 05/2012
1	ChemokinesIBA 03/2022
1	venglustatIBA 01/2022
1	Glucosylceramides (Glucocerebrosides)IBA 01/2022
1	GlycosphingolipidsIBA 01/2022
1	ProteomeIBA 01/2021
1	ChromograninsIBA 12/2020
1	bis(monoacylglyceryl)phosphateIBA 01/2020
1	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 01/2020
1	Anti-Anxiety Agents (Anxiolytics)IBA 01/2020
1	Hypnotics and Sedatives (Sedatives)IBA 01/2020
1	Protein Isoforms (Isoforms)IBA 01/2020
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2020
1	Ambroxol (Mucosolvan)IBA 01/2020
1	Cholinergic Antagonists (Anticholinergics)IBA 01/2020
1	Serine (L-Serine)FDA Link 01/2020
1	Antidepressive Agents (Antidepressants)IBA 01/2020
1	Antipsychotic Agents (Antipsychotics)IBA 01/2020
1	GTP Cyclohydrolase (GTP Cyclohydrolase I)IBA 01/2019
1	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 01/2019
1	GuanosineIBA 01/2019
1	Dopamine Agents (Dopaminergic Agents)IBA 01/2019
1	tau Proteins (tau Protein)IBA 01/2019
1	alpha-Galactosidase (Beano)IBA 03/2018
1	GalactosidasesIBA 01/2018
1	GlucosidasesIBA 01/2018
1	SphingolipidsIBA 11/2017
1	EpitopesIBA 01/2017
1	Leucine-Rich Repeat Serine-Threonine Protein Kinase-2IBA 10/2016
1	RNA (Ribonucleic Acid)IBA 01/2016
1	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 01/2016
1	DNA (Deoxyribonucleic Acid)IBA 01/2016
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 10/2015
1	Genetic Markers (Genetic Marker)IBA 06/2015
1	GD3 ganglioside (GD(3))IBA 09/2014
1	dimemorfan (AT 17)IBA 01/2014
1	Mitochondrial DNA (mtDNA)IBA 11/2012
1	TeaIBA 07/2011
1	Botulinum Toxins (Botulinum Toxin)IBA 05/2010

Therapy/Procedure

5	Therapeutics 01/2021 - 10/2015
4	Precision Medicine 02/2021 - 01/2020
3	Deep Brain Stimulation 01/2022 - 07/2016
1	Activities of Daily Living (ADL) 10/2016
1	Mediterranean Diet 05/2012
1	Nebulizers and Vaporizers (Inhaler) 07/2011